Derivation of a clinical decision rule for a bone marrow aspirate concentrate injection in knee osteoarthritis.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING

Regenerative medicine Pub Date : 2023-06-01 DOI:10.2217/rme-2023-0014

Ashley D Smith, Dasan Sydora, Robert Burnham

引用次数: 0

Abstract

Aim: To develop a simple clinical decision rule (CDR) to identify people with knee osteoarthritis who are likely or unlikely to benefit from bone marrow aspirate concentrate (BMAC) injection. Materials & methods: A total of 92 people with clinical and radiographic evidence of refractory knee osteoarthritis received a single intra-articular (IA) BMAC injection. Multiple logistic regression analysis was used to determine which combination of risk factors predicted BMAC responsiveness. A responder was defined as a person whose knee pain improved more than 15% from baseline 6 months post procedure. Results: The CDR demonstrated that those with lower pain levels, or high pain levels with previous surgery, could be predicted to benefit from a single IA BMAC injection. Conclusion: A simple CDR containing three variables predicted responsiveness to a single IA knee BMAC injection with high accuracy. Further validation of the CDR is required prior to routine use in clinical practice.

查看原文本刊更多论文

骨髓浓缩液注射治疗膝骨关节炎的临床决策规则的推导。

目的:建立一个简单的临床决策规则(CDR)，以确定谁可能或不可能受益于骨髓浓缩物(BMAC)注射的膝骨关节炎患者。材料与方法:共有92例具有临床和影像学证据的难治性膝骨性关节炎患者接受单次关节内(IA) BMAC注射。采用多元logistic回归分析确定哪些危险因素组合可预测BMAC反应性。应答者定义为术后6个月膝关节疼痛较基线改善15%以上的患者。结果:CDR显示，疼痛程度较低或既往手术疼痛程度较高的患者可以从单次IA BMAC注射中获益。结论:一个包含三个变量的简单CDR预测对单次IA膝关节BMAC注射的反应性具有很高的准确性。在临床常规使用之前，需要对CDR进行进一步的验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.